• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

CMS consolidates coverage for Intersect ENT’s corticosteroid-eluting implant

March 8, 2021 By Sean Whooley

Intersect ENT updatedIntersect ENT (NSDQ:XENT) announced today that it received consolidated Medicare coverage for its Sinuva sinus implant.

Menlo Park, Calif.-based Intersect ENT said in a news release that CMS published an average selling price (ASP) for the Sinuva implant, providing predictability, transparency and confidence of reimbursement for providers and payers in the future.

Sinuva is a non-surgical, corticosteroid-eluting implant for treating nasal polyps in adult patients who have had ethmoid sinus surgery. It is made of a self-expanding, bioabsorbable implant structurcombinedne with the targeted delivery of mometasone furoate, an anti-inflammatory corticosteroid.

The implant offers localized drug delivery for up to 90 days directly at the disease site and can be administered in an office.

Previously, a single code covered Intersect ENT’s Propel and Sinuva bioabsorbable implant product lines. However, in January, CMS created separate and distinct codes, while the ASP has now been attached to the code for the Sinuva mometasone furoate sinus implant.

Additionally, CMS confirmed the consolidation of all coding for Sinuva under the new code, giving Sinuva “pass-through” status in ambulatory care settings for Medicare patients. Intersect ENT said the separate codes would positively impact patient and physician access by improving accuracy in claims adjudication, supporting expanded use at multiple service sites, and providing greater clarity of coverage for payers and providers.

“We are pleased that CMS consolidated Sinuva coverage to a single code and published a Sinuva ASP. These actions will help better inform ENT surgeons of the amount of implant reimbursement they can expect regardless of setting of care, thereby greatly reducing the uncertainty that can come with claims submissions,” Intersect ENT president & CEO Thomas A. West said in the release. “CMS’s recent decisions will also clearly differentiate coding for Sinuva and Propel, two very different products. This will serve to simplify and streamline coding and reimbursement across our portfolio and will support evidence-based and cost-effective care across the continuum of need in chronic rhinosinusitis.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat Tagged With: Centers for Medicare and Medicaid Services (CMS), Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS